Rice Hall James & Associates, LLC Supernus Pharmaceuticals, Inc. Transaction History

Rice Hall James & Associates, LLC

  • $1.63 Billion
  • Q1 2024

A detailed history of Rice Hall James & Associates, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 516,773 shares of SUPN stock, worth $14 Million. This represents 1.08% of its overall portfolio holdings.

Number of Shares
516,773
Previous 529,952 2.49%
Holding current value
$14 Million
Previous $15.3 Million 14.94%
% of portfolio
1.08%
Previous 0.92%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024
SELL
$27.11 - $35.17 $357,282 - $463,505
-13,179 Reduced 2.49%
516,773 $17.6 Million
Q4 2023

Feb 08, 2024
SELL
$22.72 - $29.68 $329,803 - $430,834
-14,516 Reduced 2.67%
529,952 $15.3 Million
Q3 2023

Nov 02, 2023
SELL
$27.57 - $32.91 $284,660 - $339,795
-10,325 Reduced 1.86%
544,468 $15 Million
Q2 2023

Jul 24, 2023
BUY
$29.91 - $38.73 $104,924 - $135,864
3,508 Added 0.64%
554,793 $16.7 Million
Q1 2023

May 11, 2023
SELL
$34.93 - $42.03 $2.38 Million - $2.86 Million
-68,042 Reduced 10.99%
551,285 $20 Million
Q4 2022

Jan 27, 2023
SELL
$31.09 - $37.88 $1.86 Million - $2.27 Million
-59,984 Reduced 8.83%
619,327 $0
Q3 2022

Nov 01, 2022
SELL
$28.79 - $35.41 $4.45 Million - $5.48 Million
-154,641 Reduced 18.54%
679,311 $23 Million
Q2 2022

Aug 08, 2022
SELL
$25.33 - $34.25 $531,854 - $719,147
-20,997 Reduced 2.46%
833,952 $24.1 Million
Q1 2022

May 05, 2022
SELL
$28.51 - $32.9 $54,340 - $62,707
-1,906 Reduced 0.22%
854,949 $27.6 Million
Q4 2021

Feb 14, 2022
SELL
$26.37 - $34.22 $1.53 Million - $1.99 Million
-58,026 Reduced 6.34%
856,855 $25 Million
Q3 2021

Nov 09, 2021
SELL
$23.54 - $31.39 $187,802 - $250,429
-7,978 Reduced 0.86%
914,881 $24.4 Million
Q2 2021

Jul 29, 2021
SELL
$26.72 - $33.19 $3 Million - $3.72 Million
-112,230 Reduced 10.84%
922,859 $28.4 Million
Q1 2021

May 14, 2021
SELL
$24.15 - $31.45 $55,279 - $71,989
-2,289 Reduced 0.22%
1,035,089 $27.1 Million
Q4 2020

Feb 16, 2021
BUY
$17.7 - $25.81 $491,422 - $716,588
27,764 Added 2.75%
1,037,378 $26.1 Million
Q3 2020

Nov 16, 2020
BUY
$20.2 - $25.05 $1.7 Million - $2.11 Million
84,128 Added 9.09%
1,009,614 $21 Million
Q2 2020

Aug 14, 2020
SELL
$17.09 - $24.89 $377,159 - $549,297
-22,069 Reduced 2.33%
925,486 $22 Million
Q1 2020

May 15, 2020
SELL
$14.45 - $24.69 $208,340 - $355,980
-14,418 Reduced 1.5%
947,555 $17 Million
Q4 2019

Jan 29, 2020
BUY
$19.93 - $29.13 $496,257 - $725,337
24,900 Added 2.66%
961,973 $22.8 Million
Q3 2019

Oct 30, 2019
SELL
$25.47 - $33.37 $10.6 Million - $13.8 Million
-414,213 Reduced 30.65%
937,073 $25.8 Million
Q2 2019

Aug 01, 2019
BUY
$29.96 - $38.87 $10.5 Million - $13.6 Million
350,905 Added 35.08%
1,351,286 $44.7 Million
Q1 2019

May 01, 2019
BUY
$32.77 - $41.99 $2.84 Million - $3.64 Million
86,645 Added 9.48%
1,000,381 $35.1 Million
Q4 2018

Feb 14, 2019
BUY
$30.84 - $49.51 $8.48 Million - $13.6 Million
274,844 Added 43.02%
913,736 $30.4 Million
Q3 2018

Oct 25, 2018
SELL
$42.7 - $56.55 $6.99 Million - $9.26 Million
-163,769 Reduced 20.4%
638,892 $32.2 Million
Q2 2018

Aug 02, 2018
SELL
$44.1 - $59.85 $22 Million - $29.9 Million
-499,067 Reduced 38.34%
802,661 $48 Million
Q1 2018

Apr 25, 2018
SELL
$37.15 - $46.9 $775,914 - $979,553
-20,886 Reduced 1.58%
1,301,728 $59.6 Million
Q4 2017

Jan 23, 2018
BUY
$36.4 - $42.6 $3.58 Million - $4.19 Million
98,297 Added 8.03%
1,322,614 $52.7 Million
Q3 2017

Oct 30, 2017
BUY
$36.75 - $49.65 $45 Million - $60.8 Million
1,224,317
1,224,317 $49 Million

Others Institutions Holding SUPN

# of Institutions
260
Shares Held
57.3M
Call Options Held
84.1K
Put Options Held
61.2K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.45B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email